Biomarker Predictors for Immunotherapy Benefit in Breast: Beyond PD-L1
- 35 Downloads
Purpose of Review
Immune checkpoint blockade (ICB) has changed the clinical course of multiple cancer types and durable responses have now been observed in breast cancer (BC) patients. Most data suggest that, compared to other subtypes, triple-negative BC (TNBC) patients are more responsive to ICB, and anti-PD-L1 therapy is now approved in PD-L1+ metastatic TNBC, in combination with chemotherapy.
Nearly 40% of PD-L1+ TNBC patients did not respond to this combination. Thus, additional biomarkers appear to be necessary to more precisely identify potential responders. A comprehensive analysis of the breast tumor microenvironment (TME) and peripheral blood may identify potential biomarkers for a more accurate selection of patients likely to respond to ICB.
Herein, we summarize key features of the breast TME, and beyond, that may hold predictive power in determining immunotherapy benefit. Incorporation of these features in controlled clinical trials may help further guide personalized care for BC immunotherapy.
KeywordsBreast cancer Biomarkers Programmed death-ligand 1
Compliance with Ethics Standards
Conflict of Interest
Justin Balko reports research support from Genentech/Roche, Bristol Myers Squibb, and Incyte Corporation; has received consulting/expert witness fees from Novartis; is an inventor on provisional patents regarding immunotherapy targets and biomarkers in cancer; and has a patent 15/376,276 pending on the use of MHC-I/II to predict response to immunotherapy. Jamaal James declares no conflicts of interest relevant to this manuscript.
Human and Animal Rights and Informed Consent
All reported studies/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional/national research committee standards, and international/national/institutional guidelines).
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 3.Oyan B, Sonmez O, Yazar A, Teomet M. Comparison of SP142 (Ventana) and SP263 (Ventana) assays to test PD-L1 expression in metastatic cancer patients to be treated with immune checkpoint inhibitors. J Clin Oncol. 2018;36(15). https://doi.org/10.1200/JCO.2018.36.15_suppl.e24306.CrossRefGoogle Scholar
- 4.• Scott M, Scorer P, Barker C, Al-Masri H. Comparison of patient populations identified by different PD-L1 assays in in triple-negative breast cancer (TNBC). Ann Oncol. 2019;30. Comparison FDA-approved PD-L1 IHC assays testing predictive accuracy in TNBC. Google Scholar
- 7.•• Schmid P, Cruz C, Braiteh FS, Eder JP, Tolaney S, Kuter I et al. Atezolizumab in metastatic TNBC (mTNBC): Long-term clinical outcomes and biomarker analyses. Cancer Res. 2017;77. https://doi.org/10.1158/1538-7445.Am2017-2986. Dose-escalation study evaluating safety, tolerability and pharmokinetics of atezolizumab in metastatic TNBC regardless of PD-L1 expression.
- 8.•• Dirix LY, Takacs I, Jerusalem G, Nikolinakos P, Arkenau HT, Forero-Torres A, et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. Breast Cancer Res Treat. 2018;167(3):671–86. https://doi.org/10.1007/s10549-017-4537-5. Dose-escalation study testing avelumab activity and the predictive capacity of PD-L1 in metastatic BC patients who resisted standard-of-care treatment. CrossRefPubMedGoogle Scholar
- 9.•• Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018;379(22):2108–21. https://doi.org/10.1056/NEJMoa1809615. Randomized trial testing standard-of-care nab-paclitaxel in combination with atezolizumab in patients with untreated metastatic TNBC. CrossRefPubMedGoogle Scholar
- 11.Dannenfelser R, Nome M, Tahiri A, Ursini-Siegel J, Vollan HKM, Haakensen VD, et al. Data-driven analysis of immune infiltrate in a large cohort of breast cancer and its association with disease progression, ER activity, and genomic complexity. Oncotarget. 2017;8(34):57121–33. https://doi.org/10.18632/oncotarget.19078.CrossRefPubMedPubMedCentralGoogle Scholar
- 14.Cortet M, Bertaut A, Molinie F, Bara S, Beltjens F, Coutant C, et al. Trends in molecular subtypes of breast cancer: description of incidence rates between 2007 and 2012 from three French registries. BMC Cancer. 2018;18(1):161. https://doi.org/10.1186/s12885-018-4080-8.CrossRefPubMedPubMedCentralGoogle Scholar
- 23.Yao Y, Dai W. Genomic Instability and Cancer. J Carcinog Mutagen. 2014;5. https://doi.org/10.4172/2157-2518.1000165.
- 27.• Thomas A, Routh ED, Pullikuth A, Jin G, Su J, Chou JW, et al. Tumor mutational burden is a determinant of immune-mediated survival in breast cancer. Oncoimmunology. 2018;7(10):e1490854. https://doi.org/10.1080/2162402X.2018.1490854. A study using publicly available datasets to determine the prognostic value of TMB and its relationship with immune cell infiltration and BC subtype. CrossRefPubMedPubMedCentralGoogle Scholar
- 28.• Barroso-Sousa R, Jain E, Kim D, Partridge AH, Cohen O, Wagle N. Determinants of high tumor mutational burden (TMB) and mutational signatures in breast cancer. J Clin Oncol. 2018;36(15). https://doi.org/10.1200/JCO.2018.36.15_suppl.1010. A study using publicly available datasets to understand relationships between TMB and BC subtype, tumor stage, metastatic site, and mutational patterns. CrossRefGoogle Scholar
- 29.Alva AS, Mangat PK, Garrett-Mayer E, Halabi S, Alvarez RH, Calfa CJ, et al. Pembrolizumab (P) in patients (pts) with metastatic breast cancer (MBC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. J Clin Oncol. 2019;37(suppl):1014.CrossRefGoogle Scholar
- 31.Miller A, Asmann Y, Cattaneo L, Braggio E, Keats J, Auclair D, et al. High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma. Blood Cancer J. 2017;7(9):e612. https://doi.org/10.1038/bcj.2017.94.CrossRefPubMedPubMedCentralGoogle Scholar
- 32.• Santa-Maria CA, Kato T, Park JH, Kiyotani K, Rademaker A, Shah AN, et al. A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancer. Oncotarget. 2018;9(27):18985–96. https://doi.org/10.18632/oncotarget.24867. A single arm pilot study aimed at evaluating ORR in metastatic ER-positive or TNBC patients treated with durvalumab and tremelimumab. CrossRefPubMedPubMedCentralGoogle Scholar
- 35.Manuel M, Tredan O, Bachelot T, Clapisson G, Courtier A, Parmentier G, et al. Lymphopenia combined with low TCR diversity (divpenia) predicts poor overall survival in metastatic breast cancer patients. Oncoimmunology. 2012;1(4):432–40. https://doi.org/10.4161/onci.19545.CrossRefPubMedPubMedCentralGoogle Scholar
- 37.Vanderwalde A, Spetzler D, Xiao N, Gatalica Z, Marshall J. Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients. Cancer Med. 2018;7(3):746–56. https://doi.org/10.1002/cam4.1372.CrossRefPubMedPubMedCentralGoogle Scholar
- 39.Lenz HJJ, Van Cutsem E, Limon ML, Wong KY, Hendlisz A, Aglietta M, et al. Durable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC). Ann Oncol. 2018;29:714.Google Scholar
- 43.•• Kok M, Horlings HM, Snaebjornsson P, Chalabi M, Schumacher TN, Blank CU, et al. Profound Immunotherapy Response in Mismatch Repair-Deficient Breast Cancer. Jco Precis Oncol. 2017;1. https://doi.org/10.1200/Po.17.00052. An ongoing report of a single patient with pre-treated, MSI-H metastatic TNBC who benefitted from nivolumab treatment.
- 44.•• Fremd C, Hlevnjak M, Zapatka M, Zoernig I, Halama N, Fejzibegovic N, et al. Mismatch Repair Deficiency Drives Durable Complete Remission by Targeting Programmed Death Receptor 1 in a Metastatic Luminal Breast Cancer Patient. Breast Care (Basel). 2019;14(1):53–9. https://doi.org/10.1159/000492580. A report of rapid response and durable complete remission in a single patient with MSI-H metastatic luminal breast cancer treated with pembrolizumab monotherapy. CrossRefGoogle Scholar
- 45.Godet I, Gilkes DM. BRCA1 and BRCA2 mutations and treatment strategies for breast cancer. Integr Cancer Sci Ther. 2017;4(1). https://doi.org/10.15761/ICST.1000228.
- 48.Lakhani SR, Jacquemier J, Sloane JP, Gusterson BA, Anderson TJ, van de Vijver MJ, et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst. 1998;90(15):1138–45. https://doi.org/10.1093/jnci/90.15.1138.CrossRefPubMedGoogle Scholar
- 51.Higuchi T, Flies DB, Marjon NA, Mantia-Smaldone G, Ronner L, Gimotty PA, et al. CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer. Cancer Immunol Res. 2015;3(11):1257–68. https://doi.org/10.1158/2326-6066.CIR-15-0044.CrossRefPubMedPubMedCentralGoogle Scholar
- 53.• Emens LA, Loi S, Rugo HS, Schneeweiss A, Dieras V, Iwata H, et al., editors. IMpassion130: Efficacy in immune biomarker subgroups from the global, randomized, double-blind, placebo-controlled, phase III study of atezolizumab + nab-paclitaxel in patients with treatment-naïve, locally advanced or metastatic triple-negative breast cancer. San Antonio Breast Cancer Symposium; 2018 December 4-8, San Antonio, Texas; 2018. Further analysis of data gathered in the IMpassion130 trial exploring nab-paclitaxel/atezolizumab efficacy in biomarker-defined subgroups. Google Scholar
- 55.Criscuolo D, Morra F, Giannella R, Visconti R, Cerrato A, Celetti A. New combinatorial strategies to improve the PARP inhibitors efficacy in the urothelial bladder Cancer treatment. J Exp Clin Cancer Res. 2019;38(1):91. https://doi.org/10.1186/s13046-019-1089-z.CrossRefPubMedPubMedCentralGoogle Scholar
- 57.Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013;31:51–72. https://doi.org/10.1146/annurev-immunol-032712-100008.CrossRefPubMedGoogle Scholar
- 58.Chao MP, Jaiswal S, Weissman-Tsukamoto R, Alizadeh AA, Gentles AJ, Volkmer J, et al. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med. 2010;2(63):63ra94. https://doi.org/10.1126/scitranslmed.3001375.CrossRefPubMedPubMedCentralGoogle Scholar
- 63.• Lu J, Liu X, Liao YP, Wang X, Ahmed A, Jiang W, et al. Breast Cancer Chemo-immunotherapy through Liposomal Delivery of an Immunogenic Cell Death Stimulus Plus Interference in the IDO-1 Pathway. ACS Nano. 2018;12(11):11041–61. https://doi.org/10.1021/acsnano.8b05189. A preclinical study testing the effects of stimulating ICD with doxorubicin before treating with IDO-1-inhibitor, indoximod in mice with BC tumors. CrossRefPubMedPubMedCentralGoogle Scholar
- 65.Loi S, Dushyanthen S, Beavis PA, Salgado R, Denkert C, Savas P, et al. RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors. Clin Cancer Res. 2016;22(6):1499–509. https://doi.org/10.1158/1078-0432.CCR-15-1125.CrossRefPubMedGoogle Scholar
- 66.Johnson DB, Nixon MJ, Wang Y, Wang DY, Castellanos E, Estrada MV, et al. Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement. JCI Insight. 2018;3(24). https://doi.org/10.1172/jci.insight.120360.
- 67.Johnson DB, Estrada MV, Salgado R, Sanchez V, Doxie DB, Opalenik SR, et al. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. Nat Commun. 2016;7:10582. https://doi.org/10.1038/ncomms10582.CrossRefPubMedPubMedCentralGoogle Scholar
- 68.Roemer MGM, Redd RA, Cader FZ, Pak CJ, Abdelrahman S, Ouyang J, et al. Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma. J Clin Oncol. 2018;36(10):942–50. https://doi.org/10.1200/JCO.2017.77.3994.CrossRefPubMedPubMedCentralGoogle Scholar
- 70.•• Wulfkuhle JD, Yau C, Wolf DM, Gallagher RI, Swigart LB, Hirst GL, et al. Quantitative MHC II protein expression levels in tumor epithelium to predict response to the PD1 inhibitor pembrolizumab in the I-SPY 2 Trial. J Clin Oncol. 2019;37(15_suppl):2631. https://doi.org/10.1200/JCO.2019.37.15_suppl.2631. A phase 2 trial testing MHC-II as a predictive biomarker in TNBC patients treated with pembrolizumab. CrossRefGoogle Scholar
- 71.Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2015;26(2):259–71. https://doi.org/10.1093/annonc/mdu450.CrossRefPubMedGoogle Scholar
- 73.Mao Y, Qu Q, Zhang Y, Liu J, Chen X, Shen K. The value of tumor infiltrating lymphocytes (TILs) for predicting response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis. PLoS One 2014;9(12):e115103. https://doi.org/10.1371/journal.pone.0115103.CrossRefGoogle Scholar
- 76.Takada K, Kashiwagi S, Goto W, Asano Y, Takahashi K, Takashima T, et al. Use of the tumor-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to combination therapy with pertuzumab, trastuzumab, and docetaxel for advanced HER2-positive breast cancer. J Transl Med. 2018;16(1):86. https://doi.org/10.1186/s12967-018-1460-4.CrossRefPubMedPubMedCentralGoogle Scholar
- 78.Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014;32(27):2959–66. https://doi.org/10.1200/JCO.2013.55.0491.CrossRefPubMedPubMedCentralGoogle Scholar
- 80.Kurozumi S, Yamaguchi Y, Matsumoto H, Kurosumi M, Hayashi SI, Fujii T, et al. Utility of Ki67 labeling index, cyclin D1 expression, and ER-activity level in postmenopausal ER-positive and HER2-negative breast cancer with neoadjuvant chemo-endocrine therapy. PLoS One. 2019;14(5):e0217279. https://doi.org/10.1371/journal.pone.0217279.CrossRefPubMedPubMedCentralGoogle Scholar
- 81.Jiang X, Orr BA, Kranz DM, Shapiro DJ. Estrogen induction of the granzyme B inhibitor, proteinase inhibitor 9, protects cells against apoptosis mediated by cytotoxic T lymphocytes and natural killer cells. Endocrinology. 2006;147(3):1419–26. https://doi.org/10.1210/en.2005-0996.CrossRefPubMedGoogle Scholar
- 82.Svoronos N, Perales-Puchalt A, Allegrezza MJ, Rutkowski MR, Payne KK, Tesone AJ, et al. Tumor Cell-Independent Estrogen Signaling Drives Disease Progression through Mobilization of Myeloid-Derived Suppressor Cells. Cancer Discov. 2017;7(1):72–85. https://doi.org/10.1158/2159-8290.CD-16-0502.CrossRefPubMedGoogle Scholar
- 84.Kozasa K, Mabuchi S, Matsumoto Y, Kuroda H, Yokoi E, Komura N, et al. Estrogen stimulates female cancer progression by inducing myeloid-derived suppressive cells: investigations on pregnant and non-pregnant experimental models. Oncotarget. 2019;10(20):1887–902. https://doi.org/10.18632/oncotarget.26711.CrossRefPubMedPubMedCentralGoogle Scholar
- 87.Mezquita L, Auclin E, Ferrara R, Charrier M, Remon J, Planchard D, et al. Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer. JAMA Oncol. 2018;4(3):351–7. https://doi.org/10.1001/jamaoncol.2017.4771.CrossRefPubMedPubMedCentralGoogle Scholar
- 95.• Nanda R, Chow LQ, Dees EC, Berger R, Gupta S, Geva R, et al. Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. J Clin Oncol. 2016;34(21):2460–7. https://doi.org/10.1200/JCO.2015.64.8931. A non-randomized phase Ib study of testing safety and clinical activity of pembrolizumab monotherapy in patients with heavily pretreated, advanced TNBC. CrossRefPubMedPubMedCentralGoogle Scholar
- 96.• Adams S, Schmid P, Rugo HS, Winer EP, Loirat D, Awada A, et al. Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A. J Clin Oncol. 2017;35. https://doi.org/10.1200/JCO.2017.35.15_suppl.1008. A phase 2 trial testing pembrolizumab safety and responses in metastatic TNBC patients who had previously received chemotherapy. CrossRefGoogle Scholar